Security National Bank Has $6.88 Million Position in Amgen Inc. (NASDAQ:AMGN)


Share on StockTwits

Security National Bank boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 17.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 27,633 shares of the medical research company’s stock after purchasing an additional 4,099 shares during the quarter. Amgen comprises approximately 2.0% of Security National Bank’s investment portfolio, making the stock its 21st largest holding. Security National Bank’s holdings in Amgen were worth $6,875,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Advisory Alpha LLC acquired a new stake in Amgen in the 3rd quarter valued at $25,000. Fort Pitt Capital Group LLC acquired a new stake in Amgen in the 4th quarter valued at $28,000. Norway Savings Bank acquired a new stake in Amgen in the 4th quarter valued at $29,000. Crescent Capital Consulting LLC acquired a new stake in Amgen in the 4th quarter valued at $34,000. Finally, Kinloch Capital LLC acquired a new stake in Amgen in the 4th quarter valued at $40,000. 75.23% of the stock is owned by institutional investors and hedge funds.

In other news, Director R Sanders Williams sold 250 shares of the company’s stock in a transaction dated Monday, February 8th. The stock was sold at an average price of $237.99, for a total transaction of $59,497.50. Following the sale, the director now directly owns 4,659 shares in the company, valued at $1,108,795.41. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Jonathan P. Graham sold 11,110 shares of the company’s stock in a transaction dated Thursday, February 4th. The shares were sold at an average price of $236.51, for a total value of $2,627,626.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,360 shares of company stock worth $3,393,044. Company insiders own 0.36% of the company’s stock.

AMGN has been the topic of a number of analyst reports. Cantor Fitzgerald lifted their price objective on shares of Amgen from $280.00 to $295.00 and gave the stock an “overweight” rating in a report on Wednesday, February 3rd. The Goldman Sachs Group set a $277.00 price objective on shares of Amgen and gave the stock a “buy” rating in a report on Thursday, March 4th. Barclays cut their price objective on shares of Amgen from $242.00 to $230.00 and set an “equal weight” rating on the stock in a report on Thursday, March 11th. Daiwa Capital Markets initiated coverage on shares of Amgen in a report on Tuesday, December 29th. They set a “buy” rating and a $300.00 price objective on the stock. Finally, Morgan Stanley lifted their price objective on shares of Amgen from $277.00 to $279.00 and gave the stock an “overweight” rating in a report on Thursday, March 11th. Ten research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Amgen currently has an average rating of “Buy” and an average target price of $258.57.

Amgen stock traded down $0.37 during midday trading on Thursday, reaching $247.75. The stock had a trading volume of 26,301 shares, compared to its average volume of 2,729,896. Amgen Inc. has a 12 month low of $207.34 and a 12 month high of $276.69. The firm’s 50-day moving average price is $237.64 and its 200 day moving average price is $235.35. The firm has a market capitalization of $143.09 billion, a PE ratio of 20.00, a P/E/G ratio of 1.90 and a beta of 0.76. The company has a quick ratio of 1.88, a current ratio of 2.28 and a debt-to-equity ratio of 3.12.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Monday, February 1st. The medical research company reported $3.81 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.39 by $0.42. Amgen had a return on equity of 95.55% and a net margin of 29.42%. The business had revenue of $6.63 billion for the quarter, compared to analysts’ expectations of $6.57 billion. During the same period in the previous year, the business posted $3.64 EPS. The firm’s quarterly revenue was up 7.1% compared to the same quarter last year. Equities research analysts expect that Amgen Inc. will post 16.15 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 8th. Stockholders of record on Monday, May 17th will be given a dividend of $1.76 per share. This represents a $7.04 annualized dividend and a dividend yield of 2.84%. The ex-dividend date of this dividend is Friday, May 14th. Amgen’s dividend payout ratio is presently 47.50%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Featured Story: What is the yield curve?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.